Pathways to epilepsy surgery in children with tuberous sclerosis complex-associated epilepsy

L Gauer1, S Lagarde2, M-P Valenti-Hirsch1

  • 1Hôpitaux Universitaires de Strasbourg, Neurology Department, Strasbourg, France; Hôpitaux Universitaires de Strasbourg, Reference Centre for Rare Epilepsies (member of the ERN network EPICARE), Strasbourg, France.

Revue Neurologique
|June 12, 2024
PubMed

Insights

Epilepsy surgery can be effective in children with tuberous sclerosis complex, even with co-occurring conditions. Surgery outcomes in these children are comparable to other drug-resistant epilepsy populations.

Area of Science:

  • Neurology
  • Pediatric Epilepsy
  • Tuberous Sclerosis Complex

Background:

  • Epilepsy surgery efficacy is known in select children with tuberous sclerosis complex (TSC).
  • Patient selection and characteristics for TSC-related epilepsy surgery remain underdescribed.
  • This study details the pathways to epilepsy surgery in children with TSC over 20 years.

Purpose of the Study:

  • To describe patient selection and characteristics for epilepsy surgery in children with TSC.
  • To analyze surgical outcomes and compare them with non-surgical management.
  • To identify factors influencing surgical success in this population.

Main Methods:

  • Retrospective cohort study of 84 children with TSC and epilepsy from two French centers.
  • Data collected included demographics, clinical history, and surgical procedures.
  • Included registry matching and medical record reviews.

Main Results:

  • 19% of children underwent resective surgery, often before age four; 44% had stereotactic electroencephalography.
  • Seizure freedom was achieved in 57% at 1 year and 43% at 10 years post-surgery.
  • 52% of non-operated drug-resistant patients became seizure-free; 50% of operated patients reduced anti-seizure medications.

Conclusions:

  • Epilepsy surgery in children with TSC yields results comparable to other drug-resistant epilepsy populations.
  • Conditions like infantile spasms or developmental disorders are not absolute contraindications but may lower seizure freedom rates.
  • Non-operated patients may experience spontaneous evolution to drug-sensitive epilepsy.
Abstract

Related Concept Videos

Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
188
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
336
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
385